Skip to main content
. Author manuscript; available in PMC: 2015 Oct 1.
Published in final edited form as: Pediatr Nephrol. 2014 May 15;29(10):1957–1965. doi: 10.1007/s00467-014-2816-5

Table 4.

Comparison of antihypertensive medication use in ARPKD subjects and controls

Number of antihypertensive medications ARPKD Subjects
n (%)
Controls
n (%)
P
All
 0 3 (14%) 26 (59%) < 0.0001
 1 4 (18%) 14 (32%)
 2 or more 15 (68%) 4 (9%)
Excluding ACEi and ARB
 0 8 (36%) 38 (86%) < 0.0001
 1 8 (36%) 6 (14%)
 2 or more 6 (27%) 0 (0%)

ARPKD, autosomal recessive polycystic kidney disease; ACEi, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers